敲低RASSF9通过抑制PI3K/AKT通路提高耐药肺腺癌细胞对阿美替尼的敏感性OA
RASSF9 knockdown enhances sensitivity of drug-resistant lung adenocarcinoma cells to Almonertinib by inhibiting the PI3K/AKT pathway
目的 探讨Ras关联域的蛋白质9(RASSF9)对肺腺癌细胞阿美替尼耐药的影响,并阐明其分子机制.方法 构建RASSF9干扰慢病毒及其相应阴性对照(NC)载体,分别转染至非小细胞肺癌细胞系HCC827、人肺腺癌细胞系NCI-H1975的阿美替尼耐药细胞株(HCC827/AR、H1975/AR),即将细胞分别分为正常对照组(control)、NC组和shRASSF9组.采用浓度梯度递增法检测RASSF9敲低后阿美替尼耐药细胞株半抑制浓度(IC₅₀)的变化;采用CCK-8法、流式细胞术检测RASSF9敲低后耐药细胞增殖及凋亡;采用Western blot检测RASSF9和PI3K/Akt通路相关蛋白的表达.结果 与control组及NC组相比,shRASSF9组HCC827/AR和H1975/AR对阿美替尼IC₅₀显著降低(P<0.01).与control组及NC组比较,shRASSF9组HCC827/AR、H1975/AR细胞活力显著降低、细胞凋亡率显著增加(均P<0.01).Western blot结果显示,与control组和NC组比较,shRASSF9组HCC827/AR、H1975/AR细胞中RASSF9的表达水平及p-PI3K/PI3K、p-AKT/AKT的比值显著降低(P<0.01).结论 RASSF9敲低可降低肺腺癌耐药细胞对阿美替尼的耐药性,其作用机制与抑制PI3K/Akt信号通路相关.
Objective To investigate the effect of Ras association domain family member 9(RASSF9)on Almonertinib resistance in lung adenocarcinoma cells and clarify its molecular mechanism.Methods RASSF9 interference lentivirus and its corresponding negative control(NC)vector were constructed and transfected into Almonertinib-resistant cell lines HCC827/AR and H1975/AR,respectively.The cells were divided into control group,NC group and shRASSF9 group.The concentration gradient escalation method was used to determine the half-maximal inhibitory concentration(IC₅₀)of Almonertinib in drug-resistant cells after RASSF9 knock-down.The proliferation and apoptosis of drug-resistant cells were detected by CCK-8 assay and flow cytometry,respectively.The expressions of RASSF9 and PI3K/Akt pathway-related proteins were detected by Western blot.Results Compared with control group and NC group,the IC₅₀ values of Almonertinib to HCC827/AR and H1975/AR cells significantly decreased in shRASSF9 group(P<0.01).Compared with control group and NC group,the viabilities of drug-resistant cells significantly decreased,while the cell apoptosis rate significantly increased in shRASSF9 group(all P<0.01).Western blot analysis showed that the expression of RASSF9 and the ratios of p-PI3K/PI3K and p-AKT/AKT in HCC827/AR and H1975/AR cells in shRASSF9 group were significantly decreased compared with control group and NC group(P<0.01).Conclusion RASSF9 knockdown can reduce the resistance of lung adenocarcinoma drug-resistant cells to Almonertinib,which is associated with the inhibition of PI3K/Akt signaling pathway.
洪海宁;李芷依;张静;刘军;张松;张炳太;黄庭;王安生
蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学第一附属医院麻醉科蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学附属蚌埠第三人民医院胸外科,蚌埠 233000蚌埠医科大学第一附属医院胸外科
医药卫生
阿美替尼耐药肺腺癌RASSF9PI3K/Akt通路
Almonertinibdrug resistancelung adenocarcinomaRASSF9PI3K/Akt signaling pathway
《山西医科大学学报》 2026 (4)
361-367,7
蚌埠医科大学科技项目自然科学类重点项目(2023byzd119)
评论